Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026

Susana Banerjee, Professor, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, Team Leader in Women's Cancers at The Institute of Cancer Research, London, and Global Lead Principal Investigator of ENGOTov60/GOG3052/NCRI/RAMP201

“Patients whose tumors are wild-type for KRAS, NRAS, and/or BRAF have typically experienced response rates under 10% with trametinib, chemotherapy or endocrine therapy.”

Susana Banerjee, Professor, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, Team Leader in Women's Cancers at The Institute of Cancer Research, London, and Global Lead Principal Investigator of ENGOTov60/GOG3052/NCRI/RAMP201

“This analysis provides additional insight into molecular biology of recurrent LGSOC and suggests that targeting RAF, MEK, and FAK with avutometinib plus defactinib may provide clinically meaningful benefit beyond tumors driven by KRAS, NRAS or BRAF mutations.”

Michael Kauffman, M.D., Ph.D., President of Development at Verastem Oncology

“Taken together, the molecular profiling and external control arm analyses adds to the body of evidence of the potential of avutometinib plus defactinib to treat recurrent LGSOC in both KRAS-mutated and KRAS wild-type disease.”

Michael Kauffman, M.D., Ph.D., President of Development at Verastem Oncology

“The molecular profiling data show activity across biologically distinct subgroups of KRAS wild-type disease, including triple wild-type tumors, while the external control analysis shows higher response rates and statistically significant improvements in PFS over conventional care.”

Michael Kauffman, M.D., Ph.D., President of Development at Verastem Oncology

“Building on the established activity in KRAS-mutated recurrent LGSOC, these findings reinforce the approved use of avutometinib plus defactinib at first recurrence for patients with KRAS-mutated LGSOC, and the potential of combined RAF/MEK and FAK targeting to provide clinically meaningful benefit to a broader population of patients with KRAS wild-type recurrent LGSOC, many of whom have historically experienced poorer outcomes.”